MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, and autoimmune disorders and infectious diseases in the United States. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It is also developing Flotetuzumab, a DART molecule that targets CD123 and CD3; MGA012, a monoclonal antibody, which targets programmed cell death protein 1 (PD-1); MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; MGD019, a preclinical DART molecule designed to recognize the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company develops MGD009, a DART molecule recognizes B7-H3 and CD3; MGC018, a B7-H3 antibody-drug conjugate; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Teplizumab, an anti-CD3 monoclonal antibody to treat type 1 diabetes; MGD010, a DART molecule designed to address limitations of existing B cell-targeted therapies by binding to the CD32B and CD79B proteins found on human B cells; and MGD014, a DART molecule that targets the envelope protein of human immunodeficiency virus, or HIV-infected cells and CD3-expressing T cells. It has strategic collaborations with Incyte Corporation; Les Laboratoires Servier and Institut de Recherches Servier; and F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. The company also has a translational research agreement with NanoString Technologies, Inc. for the identification and development of biomarkers for MGD013 program. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MGNX
Previous Symbol
CUSIPN/A
Phone301-251-5172
Debt
Debt-to-Equity RatioN/A
Current Ratio5.95
Quick Ratio5.95
Price-To-Earnings
Trailing P/E Ratio-26.52
Forward P/E Ratio-3.39
P/E GrowthN/A
Sales & Book Value
Annual Sales$157.74 million
Price / Sales3.84
Cash FlowN/A
Price / Cash FlowN/A
Book Value$8.13 per share
Price / Book1.76
Profitability
EPS (Most Recent Fiscal Year)($0.54)
Net Income$-19,620,000.00
Net Margins-10.72%
Return on Equity-7.39%
Return on Assets-5.85%
Miscellaneous
Employees330
Outstanding Shares42,260,000
Market Cap$693.47 million
OptionableOptionable
MacroGenics (NASDAQ:MGNX) Frequently Asked Questions
What is MacroGenics' stock symbol?
MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."
How were MacroGenics' earnings last quarter?
MacroGenics Inc (NASDAQ:MGNX) posted its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.81) EPS for the quarter, beating the Zacks' consensus estimate of ($1.29) by $0.48. The biopharmaceutical company had revenue of $20.80 million for the quarter, compared to analysts' expectations of $6.18 million. MacroGenics had a negative return on equity of 7.39% and a negative net margin of 10.72%. View MacroGenics' Earnings History.
When is MacroGenics' next earnings date?
What price target have analysts set for MGNX?
9 analysts have issued 12 month price objectives for MacroGenics' shares. Their forecasts range from $21.00 to $44.00. On average, they expect MacroGenics' stock price to reach $32.1667 in the next twelve months. This suggests a possible upside of 124.6% from the stock's current price. View Analyst Price Targets for MacroGenics.
What is the consensus analysts' recommendation for MacroGenics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 1 sell rating, 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MacroGenics.
What are Wall Street analysts saying about MacroGenics stock?
Here are some recent quotes from research analysts about MacroGenics stock:
- 1. HC Wainwright analysts commented, "Our 12-month, $34 price target for shares of MacroGenics is based on a 13-year DCF-driven sum-of-the-parts analysis. Our DCF is driven by: beta of 1.68, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 11.4%, and tax rate of 15% beginning in FY 2027. (19%), flotetuzumab (17%) together represent about 99% of our target." (11/29/2018)
- 2. According to Zacks Investment Research, "MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. " (11/13/2018)
- 3. Cowen Inc analysts commented, "We hosted SAGE’s CFO Kimi Iguchi and CMO Steve Kanes at our 2018 Boston, MA. While our discussion touched upon several topics, the most important takeaway in our view was that management appears very confident heading into the 4Q18 availability of top-line pivotal trial data on SAGE-217 in postpartum depression (PPD). We believe this is a key stock driver as these data have a read-through for the development of SAGE-217 in major depressive disorder (MDD), which is a significantly larger indication vs. PPD (see here). Recall that SAGE-217 is an oral, small-molecule product with a novel mechanism of action. If approved, SAGE-217 could change the treatment paradigm from the current standard of care that relies on chronic treatment of MDD to an episodic one." (8/8/2018)
Has MacroGenics been receiving favorable news coverage?
Headlines about MGNX stock have trended extremely positive recently, according to InfoTrie. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. MacroGenics earned a daily sentiment score of 5.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next several days.
Who are some of MacroGenics' key competitors?
Some companies that are related to MacroGenics include Ascendis Pharma A/S (ASND), Allakos (ALLK), Endo International (ENDP), Blueprint Medicines (BPMC), Ultragenyx Pharmaceutical (RARE), Myokardia (MYOK), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Xencor (XNCR), Heron Therapeutics (HRTX), Arena Pharmaceuticals (ARNA), Endocyte (ECYT), AnaptysBio (ANAB), Supernus Pharmaceuticals (SUPN) and Pacira Pharmaceuticals (PCRX).
Who are MacroGenics' key executives?
MacroGenics' management team includes the folowing people:
- Dr. Scott Koenig, CEO, Pres & Director (Age 66)
- Mr. James Karrels, Sr. VP, CFO & Sec. (Age 51)
- Dr. Ezio Bonvini, Sr. VP of Research & Chief Scientific Officer (Age 64)
- Mr. Eric Blasius Risser, Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer (Age 45)
- Dr. Jon M. Wigginton, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 56)
Who are MacroGenics' major shareholders?
MacroGenics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.64%), BB Biotech AG (7.08%), FMR LLC (6.20%), Vanguard Group Inc. (5.37%), EcoR1 Capital LLC (3.50%) and Point72 Asset Management L.P. (2.68%). Company insiders that own MacroGenics stock include Eric Blasius Risser, James Karrels, Jon Marc Wigginton and Lynn Cilinski. View Institutional Ownership Trends for MacroGenics.
Which institutional investors are selling MacroGenics stock?
MGNX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Prosight Management LP, Renaissance Technologies LLC, Pinnacle Associates Ltd., Victory Capital Management Inc., Franklin Resources Inc., Virtus ETF Advisers LLC and BlueMountain Capital Management LLC. Company insiders that have sold MacroGenics company stock in the last year include Eric Blasius Risser, James Karrels, Jon Marc Wigginton and Lynn Cilinski. View Insider Buying and Selling for MacroGenics.
Which institutional investors are buying MacroGenics stock?
MGNX stock was bought by a variety of institutional investors in the last quarter, including BB Biotech AG, Dimensional Fund Advisors LP, Candriam Luxembourg S.C.A., DekaBank Deutsche Girozentrale, Vanguard Group Inc., Bellevue Group AG, BlackRock Inc. and AXA. View Insider Buying and Selling for MacroGenics.
How do I buy shares of MacroGenics?
Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MacroGenics' stock price today?
One share of MGNX stock can currently be purchased for approximately $14.32.
How big of a company is MacroGenics?
MacroGenics has a market capitalization of $693.47 million and generates $157.74 million in revenue each year. The biopharmaceutical company earns $-19,620,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. MacroGenics employs 330 workers across the globe.
What is MacroGenics' official website?
How can I contact MacroGenics?
MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.
MarketBeat Community Rating for MacroGenics (NASDAQ MGNX)
MarketBeat's community ratings are surveys of what our community members think about MacroGenics and other stocks. Vote "Outperform" if you believe MGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
